Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Graft vs Host Disease | 101 | 2024 | 2958 | 9.150 |
Why?
|
Hematopoietic Stem Cell Transplantation | 115 | 2024 | 5445 | 7.090 |
Why?
|
Transplantation Conditioning | 53 | 2024 | 1599 | 4.830 |
Why?
|
Hematologic Neoplasms | 29 | 2018 | 1832 | 2.310 |
Why?
|
Interleukin-2 | 14 | 2023 | 1904 | 2.240 |
Why?
|
Myelodysplastic Syndromes | 18 | 2020 | 1352 | 1.760 |
Why?
|
Transplantation, Homologous | 61 | 2024 | 4777 | 1.750 |
Why?
|
T-Lymphocytes, Regulatory | 19 | 2022 | 2988 | 1.680 |
Why?
|
Leukemia, Myeloid, Acute | 22 | 2024 | 3524 | 1.500 |
Why?
|
Tacrolimus | 13 | 2023 | 743 | 1.400 |
Why?
|
Cord Blood Stem Cell Transplantation | 15 | 2019 | 314 | 1.310 |
Why?
|
Myeloablative Agonists | 13 | 2019 | 218 | 1.260 |
Why?
|
HLA Antigens | 8 | 2020 | 1382 | 1.180 |
Why?
|
Boronic Acids | 4 | 2014 | 965 | 1.020 |
Why?
|
Graft vs Tumor Effect | 2 | 2016 | 72 | 0.960 |
Why?
|
Pyrazines | 4 | 2014 | 1230 | 0.920 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2023 | 97 | 0.810 |
Why?
|
Chronic Disease | 32 | 2024 | 9139 | 0.700 |
Why?
|
Photopheresis | 1 | 2019 | 24 | 0.680 |
Why?
|
Transplantation, Autologous | 13 | 2022 | 2123 | 0.670 |
Why?
|
Recurrence | 25 | 2024 | 8337 | 0.650 |
Why?
|
Histocompatibility | 3 | 2015 | 330 | 0.640 |
Why?
|
Lymphoproliferative Disorders | 2 | 2020 | 524 | 0.630 |
Why?
|
Hepatic Veno-Occlusive Disease | 6 | 2022 | 220 | 0.630 |
Why?
|
Chromosomes, Human, Pair 11 | 6 | 1999 | 417 | 0.620 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2023 | 570 | 0.620 |
Why?
|
Killer Cells, Natural | 7 | 2022 | 2131 | 0.620 |
Why?
|
Stem Cell Transplantation | 6 | 2017 | 1620 | 0.600 |
Why?
|
Iron Overload | 5 | 2012 | 242 | 0.590 |
Why?
|
Transplantation Chimera | 5 | 2015 | 613 | 0.550 |
Why?
|
Bronchiolitis Obliterans | 6 | 2022 | 194 | 0.550 |
Why?
|
Methotrexate | 9 | 2019 | 1726 | 0.540 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2016 | 310 | 0.530 |
Why?
|
Survival Analysis | 27 | 2018 | 10251 | 0.520 |
Why?
|
Lymphocyte Transfusion | 1 | 2016 | 236 | 0.520 |
Why?
|
Cyclophosphamide | 7 | 2023 | 2241 | 0.510 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 6 | 2016 | 272 | 0.480 |
Why?
|
Humans | 172 | 2024 | 743811 | 0.450 |
Why?
|
Adult | 103 | 2024 | 213889 | 0.450 |
Why?
|
Histocompatibility Testing | 6 | 2015 | 741 | 0.450 |
Why?
|
Paneth Cells | 1 | 2013 | 99 | 0.440 |
Why?
|
Vidarabine | 7 | 2021 | 345 | 0.440 |
Why?
|
Disease-Free Survival | 23 | 2018 | 6895 | 0.410 |
Why?
|
Azacitidine | 2 | 2024 | 347 | 0.410 |
Why?
|
Middle Aged | 99 | 2022 | 213241 | 0.410 |
Why?
|
Germinal Center | 3 | 2022 | 377 | 0.400 |
Why?
|
CD8-Positive T-Lymphocytes | 11 | 2022 | 4477 | 0.390 |
Why?
|
Busulfan | 5 | 2021 | 263 | 0.390 |
Why?
|
Aged | 79 | 2022 | 163178 | 0.380 |
Why?
|
Multiple Myeloma | 6 | 2022 | 5185 | 0.370 |
Why?
|
Fetal Blood | 7 | 2016 | 1318 | 0.370 |
Why?
|
Sirolimus | 7 | 2016 | 1565 | 0.370 |
Why?
|
Hematopoietic Stem Cells | 2 | 2020 | 3389 | 0.350 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2021 | 1596 | 0.350 |
Why?
|
Living Donors | 2 | 2015 | 621 | 0.350 |
Why?
|
Forkhead Transcription Factors | 3 | 2013 | 1613 | 0.350 |
Why?
|
Prednisone | 1 | 2014 | 1574 | 0.350 |
Why?
|
Graft vs Leukemia Effect | 3 | 2020 | 111 | 0.340 |
Why?
|
Cytomegalovirus Infections | 4 | 2023 | 820 | 0.340 |
Why?
|
Receptors, KIR | 2 | 2024 | 113 | 0.340 |
Why?
|
Erythema | 1 | 2010 | 257 | 0.340 |
Why?
|
Combined Modality Therapy | 5 | 2019 | 8637 | 0.330 |
Why?
|
Thrombotic Microangiopathies | 2 | 2022 | 132 | 0.330 |
Why?
|
Hydroxamic Acids | 1 | 2012 | 494 | 0.330 |
Why?
|
Gastrointestinal Tract | 2 | 2020 | 814 | 0.320 |
Why?
|
CD4-Positive T-Lymphocytes | 10 | 2021 | 4386 | 0.320 |
Why?
|
Male | 89 | 2021 | 349776 | 0.310 |
Why?
|
Steroids | 6 | 2022 | 930 | 0.300 |
Why?
|
Lymphoma | 6 | 2016 | 1875 | 0.300 |
Why?
|
Pulmonary Edema | 1 | 2010 | 414 | 0.300 |
Why?
|
Homeostasis | 3 | 2013 | 3337 | 0.300 |
Why?
|
Female | 95 | 2021 | 380020 | 0.300 |
Why?
|
Immunosuppressive Agents | 11 | 2020 | 4152 | 0.290 |
Why?
|
Leukemia | 8 | 2016 | 1509 | 0.290 |
Why?
|
Young Adult | 42 | 2023 | 56392 | 0.280 |
Why?
|
Acute Disease | 10 | 2020 | 7150 | 0.280 |
Why?
|
B-Lymphocytes | 8 | 2022 | 4665 | 0.270 |
Why?
|
Antineoplastic Agents | 10 | 2017 | 13691 | 0.270 |
Why?
|
Protease Inhibitors | 1 | 2009 | 792 | 0.270 |
Why?
|
Retrospective Studies | 46 | 2023 | 77410 | 0.260 |
Why?
|
T-Lymphocytes, Helper-Inducer | 5 | 2019 | 985 | 0.250 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 1670 | 0.240 |
Why?
|
T-Lymphocytes | 3 | 2020 | 10179 | 0.240 |
Why?
|
S Phase | 1 | 2005 | 423 | 0.230 |
Why?
|
Lymphocyte Activation | 7 | 2022 | 5524 | 0.230 |
Why?
|
G1 Phase | 1 | 2005 | 415 | 0.230 |
Why?
|
Dexamethasone | 3 | 2019 | 1950 | 0.230 |
Why?
|
B-Cell Activating Factor | 3 | 2014 | 119 | 0.230 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 22 | 0.220 |
Why?
|
Single-Cell Analysis | 1 | 2013 | 2177 | 0.220 |
Why?
|
Fever | 1 | 2010 | 1616 | 0.220 |
Why?
|
Remission Induction | 7 | 2019 | 2384 | 0.220 |
Why?
|
fms-Like Tyrosine Kinase 3 | 2 | 2016 | 491 | 0.210 |
Why?
|
Lymphocyte Depletion | 2 | 2016 | 608 | 0.210 |
Why?
|
Graft Survival | 8 | 2014 | 3734 | 0.210 |
Why?
|
Lymphocyte Count | 4 | 2019 | 793 | 0.200 |
Why?
|
Hematologic Diseases | 2 | 2018 | 498 | 0.200 |
Why?
|
Tissue Donors | 8 | 2022 | 2241 | 0.190 |
Why?
|
Treatment Outcome | 30 | 2020 | 63042 | 0.190 |
Why?
|
Survival Rate | 15 | 2018 | 12786 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2018 | 193 | 0.190 |
Why?
|
Opportunistic Infections | 1 | 2023 | 389 | 0.190 |
Why?
|
Caenorhabditis elegans | 3 | 2015 | 1417 | 0.190 |
Why?
|
Leukemia, Myeloid | 3 | 2021 | 707 | 0.180 |
Why?
|
Drug Resistance | 2 | 2019 | 1606 | 0.180 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 260 | 0.170 |
Why?
|
Skin Diseases | 2 | 2019 | 1066 | 0.170 |
Why?
|
Cytomegalovirus | 2 | 2017 | 733 | 0.170 |
Why?
|
Interleukin-23 | 1 | 2021 | 194 | 0.170 |
Why?
|
Leukemia, Experimental | 1 | 2020 | 246 | 0.170 |
Why?
|
BK Virus | 1 | 2020 | 129 | 0.170 |
Why?
|
Time Factors | 13 | 2019 | 40038 | 0.170 |
Why?
|
Receptors, CXCR5 | 2 | 2016 | 92 | 0.170 |
Why?
|
Herpesvirus 4, Human | 2 | 2023 | 1041 | 0.160 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2017 | 1520 | 0.160 |
Why?
|
Blood Donors | 2 | 2011 | 355 | 0.160 |
Why?
|
Mycophenolic Acid | 2 | 2019 | 343 | 0.160 |
Why?
|
Bone Marrow Transplantation | 4 | 2023 | 2764 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 11524 | 0.160 |
Why?
|
Adolescent | 32 | 2023 | 85729 | 0.160 |
Why?
|
Tretinoin | 1 | 2021 | 517 | 0.150 |
Why?
|
Chromosome Deletion | 3 | 1998 | 1396 | 0.150 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2022 | 902 | 0.150 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2021 | 651 | 0.150 |
Why?
|
Disease Progression | 7 | 2023 | 13273 | 0.150 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 437 | 0.150 |
Why?
|
DNA, Neoplasm | 4 | 2016 | 1758 | 0.150 |
Why?
|
alpha 1-Antitrypsin | 1 | 2018 | 163 | 0.150 |
Why?
|
Follow-Up Studies | 15 | 2016 | 39001 | 0.150 |
Why?
|
Antibodies | 3 | 2017 | 2459 | 0.150 |
Why?
|
Myeloproliferative Disorders | 3 | 2016 | 606 | 0.150 |
Why?
|
Sulfonamides | 2 | 2024 | 1938 | 0.150 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 892 | 0.150 |
Why?
|
Genes, Tumor Suppressor | 2 | 1999 | 1097 | 0.150 |
Why?
|
Microsatellite Repeats | 2 | 1997 | 799 | 0.140 |
Why?
|
Prognosis | 15 | 2022 | 29052 | 0.140 |
Why?
|
Genetic Markers | 4 | 1999 | 2634 | 0.140 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 973 | 0.140 |
Why?
|
Cell Proliferation | 4 | 2019 | 10477 | 0.140 |
Why?
|
Cancer Vaccines | 3 | 2014 | 1023 | 0.140 |
Why?
|
Incidence | 8 | 2023 | 20948 | 0.130 |
Why?
|
Clinical Trials as Topic | 4 | 2018 | 7908 | 0.130 |
Why?
|
Antibodies, Monoclonal | 6 | 2022 | 9272 | 0.130 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2017 | 1381 | 0.130 |
Why?
|
Tandem Repeat Sequences | 1 | 2016 | 185 | 0.130 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 246 | 0.130 |
Why?
|
Piperidines | 2 | 2021 | 1601 | 0.130 |
Why?
|
Adrenal Cortex Hormones | 3 | 2020 | 1854 | 0.130 |
Why?
|
Hodgkin Disease | 2 | 2017 | 1415 | 0.130 |
Why?
|
Patient Selection | 2 | 2020 | 4210 | 0.130 |
Why?
|
Aging | 3 | 2010 | 8655 | 0.130 |
Why?
|
Immunologic Memory | 3 | 2017 | 1347 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 890 | 0.120 |
Why?
|
Transplantation Immunology | 3 | 2016 | 546 | 0.120 |
Why?
|
Chromosome Aberrations | 2 | 2015 | 1811 | 0.120 |
Why?
|
Mediastinal Neoplasms | 1 | 2017 | 423 | 0.120 |
Why?
|
rho-Associated Kinases | 1 | 2016 | 279 | 0.120 |
Why?
|
Immunotherapy | 3 | 2023 | 4437 | 0.120 |
Why?
|
Platelet Count | 1 | 2017 | 780 | 0.120 |
Why?
|
Niacinamide | 1 | 2016 | 416 | 0.120 |
Why?
|
Drug Interactions | 1 | 2019 | 1460 | 0.120 |
Why?
|
Gene Deletion | 2 | 2019 | 2749 | 0.120 |
Why?
|
16,16-Dimethylprostaglandin E2 | 1 | 2013 | 22 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 5 | 2021 | 6539 | 0.120 |
Why?
|
Gamma Rays | 1 | 2015 | 320 | 0.120 |
Why?
|
Cohort Studies | 12 | 2018 | 40545 | 0.120 |
Why?
|
Ferritins | 4 | 2012 | 590 | 0.120 |
Why?
|
Adoptive Transfer | 1 | 2016 | 844 | 0.120 |
Why?
|
Antilymphocyte Serum | 2 | 2012 | 492 | 0.110 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2017 | 689 | 0.110 |
Why?
|
Donor Selection | 1 | 2015 | 201 | 0.110 |
Why?
|
Antigens, Surface | 1 | 2017 | 1663 | 0.110 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 528 | 0.110 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2014 | 282 | 0.110 |
Why?
|
Small Molecule Libraries | 1 | 2018 | 718 | 0.110 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 693 | 0.110 |
Why?
|
Polymerase Chain Reaction | 4 | 1997 | 6170 | 0.110 |
Why?
|
Mice, Inbred BALB C | 5 | 2020 | 6380 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1070 | 0.110 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2021 | 2942 | 0.110 |
Why?
|
Chelation Therapy | 1 | 2012 | 66 | 0.100 |
Why?
|
Limbic Encephalitis | 1 | 2012 | 34 | 0.100 |
Why?
|
Syndrome | 3 | 2018 | 3249 | 0.100 |
Why?
|
Pyridones | 1 | 2017 | 711 | 0.100 |
Why?
|
Leukocytes, Mononuclear | 2 | 2016 | 1836 | 0.100 |
Why?
|
Roseolovirus Infections | 1 | 2012 | 45 | 0.100 |
Why?
|
Prospective Studies | 14 | 2022 | 53250 | 0.100 |
Why?
|
Mutation | 7 | 2020 | 29777 | 0.100 |
Why?
|
Topography, Medical | 1 | 2011 | 37 | 0.100 |
Why?
|
STAT3 Transcription Factor | 1 | 2016 | 873 | 0.100 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1377 | 0.100 |
Why?
|
Herpesvirus 6, Human | 1 | 2012 | 95 | 0.100 |
Why?
|
Leukocyte Count | 2 | 2014 | 1588 | 0.100 |
Why?
|
Iron Chelating Agents | 1 | 2012 | 139 | 0.100 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2750 | 0.100 |
Why?
|
Lymphoma, B-Cell | 1 | 2017 | 931 | 0.100 |
Why?
|
Melphalan | 3 | 2019 | 431 | 0.100 |
Why?
|
Retinoblastoma Protein | 1 | 2015 | 705 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 2 | 2016 | 1837 | 0.100 |
Why?
|
STAT5 Transcription Factor | 3 | 2017 | 259 | 0.090 |
Why?
|
Transplantation, Isogeneic | 1 | 2010 | 257 | 0.090 |
Why?
|
Consensus | 2 | 2021 | 2954 | 0.090 |
Why?
|
Age Factors | 9 | 2020 | 18355 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1968 | 0.090 |
Why?
|
Sezary Syndrome | 1 | 2011 | 76 | 0.090 |
Why?
|
International Cooperation | 2 | 2014 | 1419 | 0.090 |
Why?
|
Observation | 1 | 2011 | 312 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5532 | 0.090 |
Why?
|
Markov Chains | 1 | 2013 | 968 | 0.090 |
Why?
|
National Institutes of Health (U.S.) | 3 | 2021 | 781 | 0.090 |
Why?
|
Transplants | 1 | 2011 | 209 | 0.090 |
Why?
|
Mycosis Fungoides | 1 | 2011 | 163 | 0.080 |
Why?
|
Lung Diseases | 1 | 2019 | 1887 | 0.080 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2011 | 134 | 0.080 |
Why?
|
Transforming Growth Factor beta | 1 | 2017 | 2006 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1063 | 0.080 |
Why?
|
Mice, Inbred C57BL | 8 | 2020 | 21824 | 0.080 |
Why?
|
Cryopreservation | 3 | 2021 | 671 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3706 | 0.080 |
Why?
|
Multiprotein Complexes | 1 | 2015 | 1120 | 0.080 |
Why?
|
Heterozygote | 1 | 1995 | 2803 | 0.080 |
Why?
|
Hypertriglyceridemia | 1 | 2011 | 295 | 0.080 |
Why?
|
Whole-Body Irradiation | 2 | 2019 | 449 | 0.080 |
Why?
|
Animals | 18 | 2022 | 168660 | 0.080 |
Why?
|
B-Lymphocyte Subsets | 1 | 2009 | 246 | 0.080 |
Why?
|
Quality of Life | 4 | 2022 | 12788 | 0.070 |
Why?
|
Child | 9 | 2023 | 77637 | 0.070 |
Why?
|
Proteins | 1 | 2022 | 6098 | 0.070 |
Why?
|
Lymphoma, Follicular | 1 | 2011 | 435 | 0.070 |
Why?
|
Hypolipidemic Agents | 1 | 2011 | 606 | 0.070 |
Why?
|
Risk Factors | 8 | 2018 | 72252 | 0.070 |
Why?
|
Viremia | 1 | 2010 | 736 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 459 | 0.070 |
Why?
|
Telomerase | 1 | 2011 | 731 | 0.070 |
Why?
|
Cell Cycle | 1 | 2015 | 2963 | 0.070 |
Why?
|
Immunity, Humoral | 1 | 2010 | 598 | 0.070 |
Why?
|
Mice, Knockout | 5 | 2020 | 14563 | 0.070 |
Why?
|
Survivors | 1 | 2016 | 2291 | 0.070 |
Why?
|
Siblings | 1 | 2010 | 853 | 0.070 |
Why?
|
Pyrimidines | 2 | 2015 | 2945 | 0.070 |
Why?
|
Leukocytes | 1 | 2014 | 2044 | 0.070 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2015 | 2453 | 0.070 |
Why?
|
Iron | 2 | 2012 | 1774 | 0.070 |
Why?
|
Parathyroid Hormone | 1 | 2012 | 1800 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 2 | 2017 | 4552 | 0.060 |
Why?
|
Haplotypes | 1 | 2011 | 2779 | 0.060 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 876 | 0.060 |
Why?
|
Immunologic Factors | 1 | 2014 | 1580 | 0.060 |
Why?
|
Blood Platelets | 2 | 2013 | 2509 | 0.060 |
Why?
|
Thymus Gland | 1 | 2010 | 1266 | 0.060 |
Why?
|
Isoantibodies | 1 | 2009 | 679 | 0.060 |
Why?
|
RNA, Helminth | 1 | 2004 | 59 | 0.060 |
Why?
|
Mice, Mutant Strains | 2 | 2019 | 1862 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2914 | 0.060 |
Why?
|
Recovery of Function | 1 | 2015 | 2922 | 0.060 |
Why?
|
Hypercholesterolemia | 1 | 2011 | 1151 | 0.060 |
Why?
|
Breast Neoplasms | 4 | 2010 | 20827 | 0.060 |
Why?
|
Immunophenotyping | 3 | 2016 | 1880 | 0.060 |
Why?
|
Pyrazoles | 1 | 2014 | 1970 | 0.060 |
Why?
|
Mice | 10 | 2022 | 81154 | 0.060 |
Why?
|
Risk | 3 | 2011 | 9677 | 0.060 |
Why?
|
Immunoprecipitation | 2 | 2017 | 906 | 0.060 |
Why?
|
Risk Assessment | 3 | 2017 | 23327 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2015 | 9944 | 0.060 |
Why?
|
Cytokines | 2 | 2016 | 7324 | 0.060 |
Why?
|
Adenine | 2 | 2021 | 935 | 0.060 |
Why?
|
Influenza Vaccines | 1 | 2010 | 738 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2013 | 1956 | 0.060 |
Why?
|
Antigens, CD | 3 | 2022 | 4026 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10940 | 0.050 |
Why?
|
Alleles | 3 | 2019 | 6934 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2023 | 9239 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 94 | 0.050 |
Why?
|
Kidney | 1 | 2018 | 7185 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2019 | 2540 | 0.050 |
Why?
|
Genome | 2 | 2004 | 1806 | 0.050 |
Why?
|
Thalidomide | 1 | 2007 | 890 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2011 | 2107 | 0.050 |
Why?
|
Macrophages | 1 | 2017 | 5651 | 0.050 |
Why?
|
Bone Marrow | 2 | 2022 | 2951 | 0.050 |
Why?
|
Disease Models, Animal | 5 | 2020 | 18027 | 0.050 |
Why?
|
Salvage Therapy | 1 | 2008 | 1275 | 0.050 |
Why?
|
Severity of Illness Index | 4 | 2020 | 15526 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5096 | 0.050 |
Why?
|
Chromosome Mapping | 4 | 1999 | 4737 | 0.050 |
Why?
|
Repressor Proteins | 3 | 2017 | 3024 | 0.050 |
Why?
|
Open Reading Frames | 1 | 2004 | 811 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 266 | 0.050 |
Why?
|
Mitochondria | 1 | 2014 | 3513 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 127 | 0.050 |
Why?
|
Forehead | 1 | 2021 | 69 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2016 | 57744 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2015 | 12354 | 0.050 |
Why?
|
Ohio | 1 | 2021 | 337 | 0.050 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 906 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2016 | 1374 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8090 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2011 | 2961 | 0.040 |
Why?
|
Odds Ratio | 2 | 2014 | 9848 | 0.040 |
Why?
|
Chromosomes, Artificial, Yeast | 1 | 1999 | 118 | 0.040 |
Why?
|
Antibodies, Viral | 1 | 2010 | 3175 | 0.040 |
Why?
|
Influenza, Human | 1 | 2010 | 1480 | 0.040 |
Why?
|
Sarcoma, Experimental | 1 | 1999 | 128 | 0.040 |
Why?
|
Flow Cytometry | 3 | 2015 | 5973 | 0.040 |
Why?
|
Mass Spectrometry | 2 | 2017 | 2203 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2017 | 1434 | 0.040 |
Why?
|
DNA, Satellite | 2 | 1995 | 69 | 0.040 |
Why?
|
Cell Count | 2 | 2016 | 1855 | 0.040 |
Why?
|
Scleroderma, Localized | 1 | 2019 | 79 | 0.040 |
Why?
|
Cytogenetic Analysis | 2 | 2010 | 294 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9582 | 0.040 |
Why?
|
United States | 7 | 2021 | 69859 | 0.040 |
Why?
|
Enzyme Inhibitors | 2 | 2022 | 3794 | 0.040 |
Why?
|
Gene Library | 2 | 2014 | 1074 | 0.040 |
Why?
|
Models, Statistical | 1 | 2012 | 5100 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2010 | 4459 | 0.040 |
Why?
|
Gene Expression | 3 | 2016 | 7793 | 0.040 |
Why?
|
Disease Management | 2 | 2020 | 2459 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2007 | 6487 | 0.040 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 1999 | 403 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 1997 | 6773 | 0.040 |
Why?
|
Fibrosarcoma | 1 | 1999 | 345 | 0.040 |
Why?
|
Lymphocyte Cooperation | 1 | 2016 | 112 | 0.030 |
Why?
|
Progesterone | 1 | 2021 | 773 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3255 | 0.030 |
Why?
|
Vaccination | 2 | 2022 | 3275 | 0.030 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2016 | 226 | 0.030 |
Why?
|
Helicobacter pylori | 1 | 1999 | 384 | 0.030 |
Why?
|
RNA Interference | 1 | 2004 | 2890 | 0.030 |
Why?
|
Human Genome Project | 1 | 1996 | 193 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2021 | 871 | 0.030 |
Why?
|
Lymphopoiesis | 1 | 2016 | 135 | 0.030 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2016 | 140 | 0.030 |
Why?
|
Cyclin D | 1 | 2015 | 72 | 0.030 |
Why?
|
Dioxygenases | 1 | 2017 | 314 | 0.030 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2016 | 227 | 0.030 |
Why?
|
Receptors, Interleukin-21 | 1 | 2014 | 33 | 0.030 |
Why?
|
Blotting, Southern | 1 | 1995 | 803 | 0.030 |
Why?
|
Child, Preschool | 4 | 2023 | 40964 | 0.030 |
Why?
|
Uterine Cervical Dysplasia | 1 | 1998 | 387 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2016 | 4803 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2017 | 620 | 0.030 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1995 | 769 | 0.030 |
Why?
|
Mouth Diseases | 1 | 2016 | 241 | 0.030 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11036 | 0.030 |
Why?
|
Stomatitis | 1 | 2016 | 267 | 0.030 |
Why?
|
Antigens, CD34 | 1 | 2016 | 658 | 0.030 |
Why?
|
Recombination, Genetic | 1 | 1999 | 1586 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2005 | 3463 | 0.030 |
Why?
|
Oxazines | 1 | 2015 | 298 | 0.030 |
Why?
|
Antigens, CD20 | 1 | 2014 | 199 | 0.030 |
Why?
|
Clone Cells | 1 | 2017 | 1692 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2016 | 881 | 0.030 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2016 | 648 | 0.030 |
Why?
|
Antibody Formation | 1 | 2017 | 1402 | 0.030 |
Why?
|
Pulmonary Fibrosis | 1 | 2017 | 530 | 0.030 |
Why?
|
Infusions, Subcutaneous | 1 | 2012 | 41 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 1999 | 2649 | 0.030 |
Why?
|
Plasma Cells | 1 | 2016 | 593 | 0.030 |
Why?
|
CD40 Ligand | 1 | 2014 | 526 | 0.030 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2015 | 323 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2012 | 68 | 0.030 |
Why?
|
Mice, Nude | 1 | 1999 | 3680 | 0.030 |
Why?
|
Bacteremia | 1 | 1999 | 963 | 0.030 |
Why?
|
Polymorphism, Genetic | 3 | 1999 | 4326 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2021 | 1271 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2016 | 1342 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2011 | 12243 | 0.030 |
Why?
|
Deferoxamine | 1 | 2012 | 151 | 0.030 |
Why?
|
Morpholines | 1 | 2015 | 571 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2018 | 1459 | 0.030 |
Why?
|
Death | 1 | 2016 | 678 | 0.030 |
Why?
|
K562 Cells | 1 | 2013 | 635 | 0.030 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2015 | 539 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2011 | 5691 | 0.020 |
Why?
|
Aminopyridines | 1 | 2015 | 543 | 0.020 |
Why?
|
Genetic Diseases, Inborn | 1 | 1996 | 588 | 0.020 |
Why?
|
Infant | 3 | 2023 | 35122 | 0.020 |
Why?
|
Cell Separation | 1 | 2016 | 1750 | 0.020 |
Why?
|
Interleukin-17 | 1 | 2017 | 902 | 0.020 |
Why?
|
Neutrophils | 2 | 2016 | 3718 | 0.020 |
Why?
|
Transfection | 1 | 1999 | 5892 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 2503 | 0.020 |
Why?
|
Karyotyping | 1 | 2012 | 1243 | 0.020 |
Why?
|
Virus Activation | 1 | 2012 | 319 | 0.020 |
Why?
|
Neoplasm Invasiveness | 2 | 1995 | 3617 | 0.020 |
Why?
|
Base Sequence | 3 | 2015 | 12798 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2560 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2019 | 2258 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1656 | 0.020 |
Why?
|
Spleen | 1 | 2016 | 2359 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2012 | 15281 | 0.020 |
Why?
|
Thrombomodulin | 1 | 2010 | 102 | 0.020 |
Why?
|
Interleukins | 1 | 2014 | 791 | 0.020 |
Why?
|
Th17 Cells | 1 | 2016 | 766 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2009 | 91 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2011 | 1095 | 0.020 |
Why?
|
Carcinoma in Situ | 1 | 1995 | 805 | 0.020 |
Why?
|
Reoperation | 1 | 2019 | 4200 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1532 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2016 | 19232 | 0.020 |
Why?
|
Molecular Sequence Data | 3 | 2015 | 18107 | 0.020 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2010 | 362 | 0.020 |
Why?
|
Caenorhabditis elegans Proteins | 1 | 2015 | 852 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2014 | 1962 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4183 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8660 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2016 | 1986 | 0.020 |
Why?
|
Calcineurin | 1 | 2008 | 226 | 0.020 |
Why?
|
Macrocyclic Compounds | 1 | 2007 | 72 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2015 | 1546 | 0.020 |
Why?
|
Receptors, Complement 3b | 1 | 2007 | 145 | 0.020 |
Why?
|
E-Selectin | 1 | 2010 | 579 | 0.020 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1995 | 1100 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2015 | 2692 | 0.020 |
Why?
|
Erythroblasts | 1 | 2007 | 150 | 0.020 |
Why?
|
Apoptosis | 2 | 2014 | 9718 | 0.020 |
Why?
|
Hematopoiesis | 1 | 2017 | 2073 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 1995 | 2924 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2274 | 0.020 |
Why?
|
Erythrocytes | 1 | 2016 | 2455 | 0.020 |
Why?
|
Phenotype | 1 | 2004 | 16361 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2016 | 2969 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2944 | 0.020 |
Why?
|
Canada | 1 | 2011 | 2064 | 0.020 |
Why?
|
von Willebrand Factor | 1 | 2010 | 669 | 0.020 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2010 | 1159 | 0.020 |
Why?
|
Carrier Proteins | 1 | 1999 | 5021 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2012 | 953 | 0.020 |
Why?
|
Liver | 2 | 2012 | 7479 | 0.020 |
Why?
|
Phosphorylation | 1 | 2017 | 8436 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2014 | 13980 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2015 | 4204 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3701 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2014 | 21733 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2010 | 808 | 0.020 |
Why?
|
Serologic Tests | 1 | 2007 | 375 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2727 | 0.020 |
Why?
|
Albumins | 1 | 2007 | 568 | 0.010 |
Why?
|
Down-Regulation | 1 | 2011 | 3000 | 0.010 |
Why?
|
Genetic Variation | 1 | 2019 | 6535 | 0.010 |
Why?
|
Rabbits | 1 | 2010 | 4894 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6356 | 0.010 |
Why?
|
Pyridines | 1 | 2015 | 2827 | 0.010 |
Why?
|
Drug Combinations | 1 | 2008 | 1958 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1366 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 3608 | 0.010 |
Why?
|
Uterine Cervical Neoplasms | 1 | 1995 | 2018 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7729 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2014 | 25609 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2012 | 5078 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2008 | 1680 | 0.010 |
Why?
|
Lymphocytes | 1 | 2010 | 2615 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8385 | 0.010 |
Why?
|
Administration, Oral | 1 | 2009 | 3912 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2010 | 3205 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15518 | 0.010 |
Why?
|
HSC70 Heat-Shock Proteins | 1 | 1999 | 51 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6620 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2017 | 9648 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 1999 | 6485 | 0.010 |
Why?
|
Pilot Projects | 1 | 2012 | 8316 | 0.010 |
Why?
|
Myocardium | 1 | 2012 | 4775 | 0.010 |
Why?
|
Data Collection | 1 | 2008 | 3339 | 0.010 |
Why?
|
Graft Rejection | 1 | 2011 | 4398 | 0.010 |
Why?
|
Papillomavirus E7 Proteins | 1 | 1998 | 123 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16674 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10380 | 0.010 |
Why?
|
Lung | 1 | 2016 | 9858 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9440 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2010 | 3482 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2009 | 4561 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 19894 | 0.010 |
Why?
|
Oncogene Proteins, Viral | 1 | 1998 | 362 | 0.010 |
Why?
|
Loss of Heterozygosity | 1 | 1998 | 684 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9310 | 0.010 |
Why?
|
Sex Factors | 1 | 2009 | 10394 | 0.010 |
Why?
|
Adenosine Triphosphatases | 1 | 1999 | 839 | 0.010 |
Why?
|
Length of Stay | 1 | 2008 | 6311 | 0.010 |
Why?
|
DNA, Bacterial | 1 | 1999 | 1463 | 0.010 |
Why?
|
Neoplasms | 2 | 2009 | 21675 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 35409 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2007 | 15067 | 0.010 |
Why?
|
DNA Primers | 1 | 1995 | 2891 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 25032 | 0.010 |
Why?
|
Genotype | 1 | 2004 | 12944 | 0.010 |
Why?
|
Signal Transduction | 1 | 2013 | 23398 | 0.010 |
Why?
|
Papillomaviridae | 1 | 1995 | 1119 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1999 | 13809 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 12066 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 15142 | 0.000 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1995 | 4033 | 0.000 |
Why?
|
Adenocarcinoma | 1 | 1995 | 6363 | 0.000 |
Why?
|